US FDA approves biosimilar aflibercept-mrbb (Ahzantive)

News
Article

The drug is a biosimilar for aflibercept 2 mg (Eylea)

A person at a desk administers a stamp that says "approved." Image credit: ©H_Ko – stock.adobe.com

In addition to Ahzantive, two other aflibercept biosimilars were recently approved by the FDA. Image credit: ©H_Ko – stock.adobe.com

The US Food and Drug Administration (FDA) announced it has approved aflibercept-mrbb (Ahzantive), biosimilar to Eylea, for the treatment of patients with age-related neovascular (wet) macular degeneration (nAMD). The news was announced in a press release from biosimilar developer Formycon AG and its licensing partner Klinge Biopharma, both based in Germany.1

The biosimilar has also been approved for treatment in patients with serious retinal diseases such as diabetic macular oedema (DME), diabetic retinopathy (DR) and macular oedema following retinal vein occlusion (RVO).

In addition to Ahzantive, two other aflibercept biosimilars were recently approved by the FDA: Biocon Biologics's aflibercept-jbvf (Yesafili) and Samsung Bioepis aflibercept-yszy (Opuviz).

In the press release,1 Formycon CEO Stefan Glombitza, PhD, stated that the FDA approval of Ahzantive was “another key milestone on [their] way to becoming the leading pure-play biosimilar developer. It highlights the expertise and experience of [their] team.” He further stated that, alongside Formycon's approved biosimilar FYB201 (reference drug Lucentis), he believes the company has an “outstanding position in ophthalmic biosimilar therapies.”

According to Formycon, the active ingredient in Ahzantive inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.

The company said that the FDA approval was rooted in the company's “comprehensive data package” that included “analytical, pre-clinical, clinical and manufacturing data.” The data showed that Ahzantive demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Eylea in patients with nAMD.

In addition to the FDA approval, the company also submitted a marketing authorisation application with the European Medicines Agency (EMA) and expects a response by early 2025.

References:
  1. Formycon Receives FDA Approval for FYB203/AHZANTIVE (AFLIBERCEPT-MRBB), a biosimilar to Eylea. Press Release. Published 1July, 2024. Accessed 2 July, 2024. https://www.formycon.com/en/blog/press-release/formycon-receives-fda-approval-for-fyb203-ahzantive/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.